HMCIB SPAC 3 (226340) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HMCIB SPAC 3 (226340) has a cash flow conversion efficiency ratio of 0.042x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.56 Billion ≈ $1.73 Million USD) by net assets (₩60.89 Billion ≈ $41.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of HMCIB SPAC 3 to measure how much of total assets are equity-financed.
HMCIB SPAC 3 - Cash Flow Conversion Efficiency Trend (2015–2023)
This chart illustrates how HMCIB SPAC 3's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HMCIB SPAC 3 cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
HMCIB SPAC 3 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HMCIB SPAC 3 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tadmax Resources Berhad
KLSE:4022
|
-0.086x |
|
Mangalam Organics Limited
NSE:MANORG
|
0.034x |
|
Lument Finance Trust Inc
NYSE:LFT
|
0.006x |
|
Senheng New Retail Bhd
KLSE:5305
|
0.046x |
|
Webus International Limited Ordinary Shares
NASDAQ:WETO
|
0.240x |
|
Bilici Yatirim Sanayi ve Ticaret AS
IS:BLCYT
|
-0.021x |
|
Havanna Holding SA
BA:HAVA
|
0.080x |
|
Korea New Network Co. Ltd
KQ:058400
|
0.023x |
Annual Cash Flow Conversion Efficiency for HMCIB SPAC 3 (2015–2023)
The table below shows the annual cash flow conversion efficiency of HMCIB SPAC 3 from 2015 to 2023. For the full company profile with market capitalisation and key ratios, see HMCIB SPAC 3 (226340) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | ₩39.84 Billion ≈ $27.00 Million |
₩4.61 Billion ≈ $3.13 Million |
0.116x | +183.54% |
| 2022-12-31 | ₩25.63 Billion ≈ $17.37 Million |
₩-3.55 Billion ≈ $-2.41 Million |
-0.139x | -251.58% |
| 2021-12-31 | ₩22.41 Billion ≈ $15.18 Million |
₩2.05 Billion ≈ $1.39 Million |
0.091x | -0.20% |
| 2020-12-31 | ₩32.52 Billion ≈ $22.04 Million |
₩2.98 Billion ≈ $2.02 Million |
0.092x | -68.80% |
| 2019-12-31 | ₩33.96 Billion ≈ $23.01 Million |
₩9.98 Billion ≈ $6.76 Million |
0.294x | +230.09% |
| 2018-12-31 | ₩24.80 Billion ≈ $16.81 Million |
₩-5.60 Billion ≈ $-3.80 Million |
-0.226x | -194.68% |
| 2017-12-31 | ₩12.67 Billion ≈ $8.59 Million |
₩3.02 Billion ≈ $2.05 Million |
0.239x | +1674.08% |
| 2016-12-31 | ₩12.56 Billion ≈ $8.51 Million |
₩168.86 Million ≈ $114.43K |
0.013x | +174.41% |
| 2015-12-31 | ₩12.40 Billion ≈ $8.41 Million |
₩-224.16 Million ≈ $-151.91K |
-0.018x | -- |
About HMCIB SPAC 3
Bonne Co., Ltd. develops and supplies cosmetics in South Korea. The company offers skin care products, including whitening, wrinkle and pimple treatment, stem-cell peptide, and nano peptide products; and sun care products comprising fluids, creams, emulsions, etc. It also provides hair and body care products; makeup products, such as foundation, powder, compact, loose powder, BB cream, eye liner,… Read more